Scientists have engineered dozens of adeno-associated virus (AAV) systems that ferry genes to specific neuron and glial subtypes in the brain and spinal cord with unprecedented accuracy. Powered by AI-selected DNA “light switches,” the vectors can switch on therapeutic or research genes only in targeted cells—eliminating the need for transgenic animals and enabling fine-grained circuit mapping, activation, or silencing.
